In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor,” published in the January 2025 issue of Allergy ...

BV + Len + R may be considered as a bridging therapy for patients with R/R DLBCL prior to chimeric antigen receptor-T or other more definitive ... v negative [<1%]), cell of origin (germinal center B ...

Interferons activate or upregulate immune cells by interacting with receptors that activate signal transducer and activator of transcription (STAT) signalling complexes. This ultimately leads to ...

A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.

Dr. David A Braun delved into detail on the molecular factors driving exceptional responses to immunotherapy in metastatic ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, ...

Because B-cell lymphoma develops in a type of white blood cell ... Higher levels of soluble tumor necrosis factor (TNF) ...

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...